STAT+: Pig kidneys to enter FDA-backed human trial subsequent yr
Wish to keep on high of the science and politics driving biotech right this moment? Join to get our biotech e-newsletter in your inbox.
Hey there. As we speak, we study the FDA is advancing a trial for gene-edited pig organs in people, see geographical discrepancies in lung most cancers trial knowledge, and extra.
The necessity-to-know this morning
- A optimistic readout of a Rapport Therapeutics seizure medication in a mid-stage medical trial despatched firm shares hovering, because the biotech introduced it might transfer the experimental drug into Part 3 trials. Learn extra from STAT reporter Andrew Joseph.
- Dianthus Therapeutics stated its experimental remedy for myasthenia gravis achieved the first objectives of a Part 2 research.
- Pfizer and BioNTech reported top-line Part 3 research outcomes displaying their Covid-19 vaccine Comirnaty elicited an immune response in opposition to essentially the most prevalent circulating pressure of the SARS-Cov-2 virus.
Enviornment BioWorks refocuses with a brand new CEO
Enviornment BioWorks, the $500 million analysis institute launched final yr by billionaire backers, has tapped ARIAD Prescription drugs co-founder Harvey Berger as CEO, reuniting him with longtime collaborator Stuart Schreiber, who shifts to chief scientific officer. The transfer follows a 30% workers lower that largely eradicated the corporate’s gene and cell remedy group, STAT’s Allison DeAngelis writes, with Berger arguing the institute had been overextended.
